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Background: Evaluating large-scale disease management interventions implemented in actual health care settings
is a complex undertaking for which universally accepted methods do not exist. Fundamental issues, such as a lack
of control patients and limited generalizability, hamper the use of the ‘gold-standard’ randomized controlled trial,
while methodological shortcomings restrict the value of observational designs. Advancing methods for disease
management evaluation in practice is pivotal to learn more about the impact of population-wide approaches.
Methods must account for the presence of heterogeneity in effects, which necessitates a more granular assessment
of outcomes.
Methods: This paper introduces multilevel regression methods as valuable techniques to evaluate ‘real-world’
disease management approaches in a manner that produces meaningful findings for everyday practice. In a worked
example, these methods are applied to retrospectively gathered routine health care data covering a cohort of
105,056 diabetes patients who receive disease management for type 2 diabetes mellitus in the Netherlands.
Multivariable, multilevel regression models are fitted to identify trends in clinical outcomes and correct for
differences in characteristics of patients (age, disease duration, health status, diabetes complications, smoking status)
and the intervention (measurement frequency and range, length of follow-up).
Results: After a median one year follow-up, the Dutch disease management approach was associated with small
average improvements in systolic blood pressure and low-density lipoprotein, while a slight deterioration occurred
in glycated hemoglobin. Differential findings suggest that patients with poorly controlled diabetes tend to benefit
most from disease management in terms of improved clinical measures. Additionally, a greater measurement
frequency was associated with better outcomes, while longer length of follow-up was accompanied by less positive
results.
(Continued on next page)* Correspondence: a.elissen@maastrichtuniversity.nl
1Department of Health Services Research, CAPHRI School for Public Health
and Primary Care, Maastricht University, Duboisdomein 30, PO Box 616
6200MD, Maastricht, the Netherlands
Full list of author information is available at the end of the article
© 2013 Elissen et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Elissen et al. BMC Medical Research Methodology 2013, 13:40 Page 2 of 12
http://www.biomedcentral.com/1471-2288/13/40(Continued from previous page)
Conclusions: Despite concerted efforts to adjust for potential sources of confounding and bias, there ultimately are
limits to the validity and reliability of findings from uncontrolled research based on routine intervention data. While
our findings are supported by previous randomized research in other settings, the trends in outcome measures
presented here may have alternative explanations. Further practice-based research, perhaps using historical data to
retrospectively construct a control group, is necessary to confirm results and learn more about the impact of
population-wide disease management.
Keywords: Chronic disease management, Quality measurement, Evaluation methodology, Multilevel regression
methods, Statistical heterogeneityBackground
Disease management is commonly defined as a ‘system
of coordinated health care interventions and communi-
cations for populations with conditions in which patient
self-care efforts are significant’ [1]. Originally developed
in the US, disease management interventions have been
introduced in many countries to address widespread
deficiencies in the care for chronically ill patients, in-
cluding fragmentation, insufficient evidence-based prac-
tice, and limited self-management support [2]. However,
especially outside of the US, available evidence about the
impact of disease management remains uncertain and
tends to be based on mostly small studies, which
frequently target high-risk patients and are performed in
academic settings [3]. Although some large-scale, realis-
tic evaluations have already been conducted [4], there
remains a need for better insight into the effects of com-
prehensive, population-based approaches, such as have
been implemented in, for example, Germany and the
Netherlands [5].
An important reason for this limited evidence base is
the lack of universally accepted methods for ‘real-world’
disease management evaluation that are both scientific-
ally sound and operationally feasible [6,7]. According to
Linden et al. [8] three fundamental limitations preclude
use of the ‘gold-standard’ randomized controlled trial
(RCT). First, from a practical perspective, population-
wide implementation of approaches can make it difficult
to find a suitable number of control subjects. Second,
withholding treatment that is assumed to be effective
from control patients poses an ethical dilemma. Third
and most important, however, the strict in- and exclu-
sion criteria limit generalizability of findings across pa-
tients and contexts. Observational research designs are
more suitable for practice-based disease management
evaluation yet commonly have methodological flaws that
limit the validity and reliability of findings [9].
Advancing existing methods for disease management
evaluation in routine situations where randomization is
not possible will be pivotal in drawing valid conclusions
about the impact of this care concept on the quality andoutcomes of chronic care provision. Evaluation methods
must account for the presence of heterogeneity in effects
of disease management, produced by differences in in-
terventions and targeted patients [10-13]. This variation
necessitates calculation of more detailed effect estimates
than the commonly assessed ‘grand means’ across large
populations of patients, if they are to be informative for
day-to-day clinical practice.
The aim of this paper is to introduce multilevel regres-
sion methods as useful techniques for the analysis of
patient data in practice-based disease management
evaluation. These methods enable researchers to identify
differences in outcomes as a function of features of the
intervention and/or patient population, and, in so doing,
support efforts to create effective and efficient disease
management strategies. The article starts with a brief,
non-technical description of the proposed analytic
approach. Subsequently, a worked example is given of its
application in the evaluation of a population-wide
disease management intervention for type 2 diabetes
mellitus implemented in the Netherlands. This evalu-
ation, which was part of the European collaborative
DISMEVAL (‘Developing and Validating Disease Man-
agement Evaluation Methods for European Health Care
Systems’) project [5,14], was designed as an uncontrolled
cohort study using routine patient data gathered retro-
spectively from clinical practice.
Multilevel regression methods: what and why?
In health research, especially studies conducted in prac-
tice settings, data commonly have a hierarchical nature,
with variable measures – such as cholesterol measure-
ments – clustered within different levels of the hierarchy
[15]. For example, in a practice-based study examining
factors that influence the use of shared-decision making
in general practice, patients would be clustered within
physicians, who in turn might be nested within group
practices. Traditional statistical methods, such as linear
regression analysis, tend to ignore the multilevel struc-
ture of routine health data and do not account for the
possibility of similarities among individuals clustered
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within clusters are often more alike than randomly
chosen individuals with regard to important characteris-
tics, such as sociodemographic features. Hence, assum-
ing that observations within clusters are uncorrelated is
not realistic and can result in false conclusions about
associations between particular variables [16,17].
Multilevel regression methods enable researchers to
explicitly include the hierarchical nature of practice data
into their analyses [15]. Similar in essence to simple
regressions, multilevel regression entails predicting an
outcome variable according to the values of one or more
explanatory variables, which may be measured at differ-
ent levels in the hierarchy [18]. The latter are usually
called covariates, i.e. characteristics that might influence
the size of a particular intervention’s effects. Person-level
covariates can enter the model in two different ways.
First, they may appear as ordinary covariates at level one
of the hierarchy. Second, they may appear in interaction
terms with intervention characteristics. These inter-
action terms capture the idea of ‘effect modification’ by
allowing the person-level variables to modify the inter-
vention effects.
Applying multilevel regression methods is of particular
relevance when patient outcomes are regarded as het-
erogeneous, as is typically the case with disease manage-
ment. In a simple two-level model, total heterogeneity in
effects can be divided into two variance components:
within-groups and between-groups [16]. Multilevel regres-
sion techniques make it possible to capitalize on this vari-
ation in three ways, the outcomes of which can support
further improvements in the quality and outcomes of dis-
ease management [19]. First, it enables identification of
subgroups of patients for whom treatment is associated
with the most positive effects. Second, it permits investiga-
tion of characteristics of an intervention, either active
(treatment features) or passive (setting features), that are
associated with favorable outcomes [18,20]. Third, it allows
for multiple factors measured at different levels in the hier-
archy to be examined together, the results of which may fa-
cilitate stratified medicine. In the remainder of this paper,
we will show how multilevel regression methods were ap-
plied in our evaluation of the Dutch approach to disease
management for type 2 diabetes.
Worked example: Dutch disease management evaluation
In 2007, the Netherlands Organization for Health Re-
search and Development (ZonMw) started a governmen-
tally subsidized pilot called the ‘Integrated Diabetes Care
research program’ to overcome existing barriers to co-
ordination of care for type 2 diabetes patients. As part of
the pilot, ten so-called ‘care groups’ – i.e. provider net-
works in primary care, gathering mostly general practi-
tioners (GPs) and affiliated personnel – were offeredfinancial incentives to start experimenting with a bun-
dled payment system that allows the different compo-
nents of outpatient care for type 2 diabetes to be
purchased, delivered, and billed as a single product (i.e.
a disease management intervention) [21,22]. Care groups
are responsible for all patients covered by their care pro-
gram; they deliver services themselves and/or subcon-
tract services from other providers, such as physical
therapists, dietitians, laboratories, and, to a limited ex-
tent, specialists [23]. A national evidence-based care
standard for type 2 diabetes care guides negotiations be-
tween care groups and health insurers on the content
and price of diabetes care programs [24].
One of the main goals of implementing the bundled
payment system was to stimulate the transfer of non-
complex chronic care from the hospital setting to gen-
eral practice, which traditionally is a strong sector in the
Netherlands and widely regarded as most suitable to
serve as ‘medical home’ for chronically ill patients [25].
Nearly all Dutch citizens are registered with a GP, who
constitutes the first point of contact for care-seeking in-
dividuals and acts as gatekeeper for secondary care [23].
Although some regional bundled payment contracts in-
clude a limited amount of specialist care, these services
are generally reserved for patients with complex and
unstable long-term health problems, such as type 1 dia-
betes patients and/or multimorbid patients.
Despite uncertainty about the effectiveness of the new
financing and delivery system, care groups with bundled
payment contracts for type 2 diabetes disease manage-
ment interventions rapidly achieved national coverage in
the Netherlands [26]. For evaluators, this broad disper-
sion, combined with the unsuitability of using historic
controls – evidence suggests that the quality of diabetes
care improves over time as a secular trend [27] – limits
the use of experimental comparisons. Thus, to analyze
the impact of the Dutch approach to disease manage-
ment for type 2 diabetes, we conducted an uncontrolled,
practice-based cohort study using multilevel regression
methods. Although these methods precluded the estab-
lishment of cause-effect relationships, they enabled us to
identify trends in outcome measures that might suggest
that components of the intervention under consideration
have an effect for (subgroups of ) type 2 diabetes patients
[28]. Our study was conducted in five steps: (1) partici-
pant selection, (2) data collection and validation, (3) vari-
able definition, (4) data analysis, (5) outcome interpretation.
Methods
Participant selection
We selected a convenience sample of 18 care groups,
which were set up between the years 2006 and 2009.
Nine groups were part of the pilot of the bundled pay-
ment system, for which they were selected ensuring
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the same criteria to include nine additional, non-
experimental groups, i.e. regional initiatives that have a
bundled payment contract for diabetes disease manage-
ment interventions with a health insurer but do not receive
(financial) support from the pilot. The 18 care groups rep-
resent all but one region of the Netherlands, employ
between 7 and 230 GPs per group, and cover patient popu-
lations ranging from 348 to 18,531 persons. From each
group, we selected all type 2 diabetes patients with at least
one registered visit to general practice during the research
period (N = 106,623), which – depending on the availability
of data – was either 20 or 24 months between January,
2008 and December, 2010. We excluded type 1 diabetes
patients (N = 1567), because they are treated primarily by
specialists.
Data collection and validation
The bundled payment system for chronic care in the
Netherlands requires care groups to register a specific
number of performance indicators for care processes
and clinical outcomes on an annual basis. We retro-
spectively gathered patient data on a selection of those
indicators from the clinical information systems of our
18 care groups. Data plausibility was verified through
range checks, we removed outliers in clinical values
based on cut-off points determined by Dutch diabetes
experts (see Table 1). Missing values were not imputed.
Because patient data were not available for the period
before introduction of the bundled payment system, we
used the last measurement of each clinical outcome reg-
istered per patient during the first year of the research
period (or first eight months, for two groups with a 20-
month research period) as baseline. Thus, the baseline
data used in this study represent data at the introduction
of the disease management intervention (i.e. bundled
payment system). Given that patients were enrolled at
different time points during the first year, using the last
measurement registered in that period as baseline was
preferred over the first measurement to minimize het-
erogeneity in follow-up duration between patients. This
is a conservative decision because for some cases a por-
tion of the program effects will be incorporated in the
baseline measurements.
To identify trends in outcome measures, we calculated
changes in clinical parameters from baseline to follow-Table 1 Cut-off points for clinical outcome data
Indicator Lower
Glycated hemoglobin (HbA1c) (mmol/mol) 18
LDL cholesterol (mmol/l) 1
Systolic blood pressure (mmHg) 70
BMI (kg/m2) 16up, which was operationalized as the last measurement
of each clinical outcome per patient registered during
the second year of the research period. Large correla-
tions between observations within person make the
choice of modeling change scores rather than separate
cross-sections compelling for maximizing statistical
power. Modeling change scores also controls for un-
measured but fixed person-level covariates. Before
conducting each outcome-specific analysis, we excluded
patients who: (1) lacked valid registrations of baseline or
follow-up measurement, or both, (2) missed registrations
of one or more of the characteristics used as covariates
in the multilevel regression analyses, and/or (3) had an
observation period between baseline and follow-up of
less than three months. The maximum length of follow-
up per patient was 23 months. The study flowchart is
shown in Figure 1.
Variable definition
To enable investigation of heterogeneity in effects on
clinical outcomes, we defined relevant variables relating
to patient characteristics and active features of the inter-
vention. Figure 2 shows a graphical conceptualization of
the included variables and the number of care groups
able to provide data on those variables.
With regard to intervention features, we coded meas-
urement frequency as the number of registrations of
each clinical outcome during follow-up. To describe
measurement range, we assessed the amount of different
outcomes registered per patient over baseline, which
could be a maximum of eight (i.e., glycated hemoglobin,
total cholesterol, low- and high-density lipoprotein, tri-
glycerides, systolic and diastolic blood pressure, and
body mass index). Duration of care was defined as an in-
dividual patient’s length of follow-up in months. To de-
scribe patients, we used these characteristics: age (in
years), disease duration (in years), health status, diabetes
complications, and smoking status. Health status was
determined by the baseline values of each clinical out-
come. Diabetes complications, registered since diagnosis
of type 2 diabetes (that is, either before or during the re-
search period), could comprise one or more of the four
most frequently registered co-occurring conditions
across the included care groups, i.e. angina pectoris,
myocardial infarction, stroke, and/or transient ischemic














































Patients under treatment 








Length of follow -up 
<3 months: N=3451
No first measurement: 
N=31,539
No second  
measurement: 
N=20,062
No first or second  
measurement: N=8693
Excluded SBP: 
Length of follow -up
<3 months:N= 3842
No first measurement:  
N=21,343
No second  
measurement: 
N=10,060
No first or second 
measurement: N=3626
Excluded HbA1c:
Length of follow-up 
<3 months: N=1244 
No first measurement:  
N=22,070
No second  
measurement:  
N=10,399
No first or second  
measurement: N=3784
Excluded BMI:
Length of follow-up 
<3 months: N=4042
No first measurement:  
N=30,670
No second  
measurement: 
N=19,520
No first or second  
measurement: 
N=12,517
Figure 1 Study flow chart.
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clinical outcomes as changes over baseline in glycated
hemoglobin (HbA1c), low-density lipoprotein (LDL),
systolic blood pressure (SBP), and body mass index
(BMI).
Data analysis
We conducted univariate analyses to describe patient
and intervention characteristics, which were reported
either as means and associated standard deviations (age,
disease duration, health status), median values (measure-
ment frequency, length of follow-up), or percentages
(diabetes complications, smoking, measurement range).
Using paired sample t-tests (two-sided, α = 0.05), we
calculated the care group-specific and overall mean dif-
ferences in clinical outcomes between baseline and
follow-up, and 95% confidence intervals. To quantify theheterogeneity in clinical results among our 18 care
groups, we calculated the I2 statistic on the basis of the
chi-square (χ2) test. I2 describes the percentage of total
variation in effects across groups that is due to hetero-
geneity rather than chance. The principal advantage of
I2 – which lies between 0 and 100% with larger values
showing increasing heterogeneity – is that it can be
calculated and compared across groups irrespective of
differences in size and type of outcome data [29].
For outcomes showing moderate (I2 > 50%) to high
(I2 > 75%) heterogeneity, multivariable, two-level hierar-
chical regression models – with patients at level one and
care groups at level two – were used to analyze the
influence of selected covariates on changes in clinical
outcomes between baseline and follow-up. Two separate
models were fit to test all covariates related to patient
and intervention characteristics, respectively. In a third
Figure 2 Overview of research variables (and registration in number of care groups).
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interaction between patient characteristics and interven-
tion features. The models used were similar to the kind
that might be fit in a multi-center study, i.e. mixed
models incorporating a random care group effect (PROC
MIXED command in the SASW 9.2 Software), which was
considered most suitable given the possibility of ‘residual
heterogeneity’ [30]. Where possible, covariates were
analyzed both as continuous and as categorical variables,
with categories based on scientific literature (age [31]
and disease duration [32]), median values (measurement
frequency and length of follow-up), or, in the case of
baseline health status, on the target values for clinical
parameters incorporated in the Dutch care standard for
type 2 diabetes [24]. Measurement range was categorized
as eight registered outcomes versus less than eight regis-
tered outcomes.
For each outcome, we calculated the intraclass correl-
ation coefficient (ICC) which describes the proportion of
total heterogeneity in effects attributable to between-group
variance rather than within-group variance [33]. We exam-
ined collinearity with the variance inflation factor (VIF): a
VIF value greater than 10 is generally taken as an indication
of serious multi-collinearity [34]. The regression coefficients
obtained from our multilevel analyses describe how a spe-
cific effect estimate changes following a unit increase in a
covariate, whether there is actually a relationship between
both is expressed in the statistical significance. We
expressed ‘explained heterogeneity’ as the percentage
change in between-group variance (τ2) and within-group
variance (σ2) after correcting for selected covariates.Results
Interpretation of results
Univariate analyses
Included in our analyses were 105,056 patients, about
half of whom (50.6%) were female. The average age of
the research population was 65.7 (±11.9) years and aver-
age disease duration 4.8 (±5.6) years. Further details are
shown in Table 2. With regard to care processes,
patients’ SBP was assessed most frequently during
follow-up (median = 4), followed by BMI (median = 3),
and HbA1c (median = 2). LDL was measured least often
(median = 1). Across groups, the average share of pa-
tients with the maximum measurement range varied
from 44.4 to 86.7%, with a mean of 62.3%. Median
length of follow-up was 12 months.
Table 3 presents the mean changes over baseline in clin-
ical outcomes across the total of 18 care groups. Overall,
we found a small, non-significant increase in HbA1c levels
between baseline and follow-up, while small but significant
reductions in mean levels were observed for LDL and SBP.
Except for BMI, all outcomes showed moderate to high
statistical heterogeneity, from 57% for SBP to 98% for
HbA1c, suggesting that the effects of the diabetes disease
management interventions on these outcomes were incon-
sistent across care groups. To elucidate this heterogeneity
and identify trends in the measured results, multilevel
regression analyses were conducted.
Multilevel regression analyses
The results of the multilevel regression analyses are
summarized in Table 4, which shows the changes in
Table 2 Characteristics of the research population




% (N) Mean ± SD
Baseline age 99.9 (105,013) 65.7 ± 11.9




71.5 (75,127) 50.2 ± 9.8
LDL cholesterol (mmol/l)
[target < 2.5]
55.9 (58,697) 2.6 ± 0.9
SBP (mmHg) [target < 140] 69.9 (73,437) 140.4 ± 18.0
BMI (kg/m2) [target < 25] 60.3 (63,341) 29.7 ± 5.2
% (N) % (N)
Diabetes complications† 94.5 (99,278)
None 84.2 (75,357)
One or more 15.8 (14,165)
Smoking status 74.6 (78,384)
No or Ex-smoker 81.6 (63,943)
Current smoker 18.4 (14,441)
NOTE: † Included were four major diabetes complications: angina pectoris,
myocardial infarction (MI), stroke, transient ischemic attack (TIA).
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HbA1c, LDL and SBP, after correcting for included
covariates, with the direction of covariate influence indi-
cated (positive or negative). We observed that the vast
majority of variance in the effects of disease manage-
ment on clinical outcomes occurred within care groups
rather than between groups, with ICCs ranging from 0.1
to 4.3% across outcomes. Simultaneously correcting for
known patient characteristics resulted in the most
considerable reductions in within-group variance in effects.
We found no evidence of multi-collinearity in any of the
regression models.
The multilevel regression model incorporating interven-
tion characteristics showed that two covariates significantly
influenced the effects of disease management in a consist-
ent manner across clinical outcomes. Whereas a greater
measurement frequency of clinical outcomes was associated
with better results on those outcomes, longer length of
follow-up was accompanied by diminishing positive effectsTable 3 Results of the univariate analyses per clinical outcom
Clinical outcome Care groups (N) Patients (N)
HbA1c (mmol/mol) 18 75,127
LDL (mmol/l) 18 58,697
SBP (mmHg) 18 73,437
BMI (kg/m2) 18 63,341
NOTE: * Statistically significant (p < 0.05).on HbA1c, LDL and SBP. The results for measurement
range were inconsistent across clinical outcomes.
The model for patient characteristics found significant
and consistent associations between baseline clinical
values and intervention effects, suggesting that the
impact of disease management becomes progressively
better as patients’ initial health values are poorer.
Figure 3 depicts how across the 18 care groups, patients
with a baseline HbA1c ≥75 mmol/mol achieved a mean
reduction in this clinical measure of 16.8 mmol/mol
(95% CI: -18.7, -15.0), whereas those starting within the
target range for HbA1c (≤53 mmol/mol) experienced a
slight deterioration in glycemic control (1.79 mmol/mol
[95% CI: 1.2, 2.4]). The HbA1c levels of those with base-
line values between 54 and 74 mmol/mol reduced by an
average of 2.6 mmol/mol (95% CI: -3.5, -1.8). For SBP
and LDL, similar trends were found. Those with poor
baseline values tended to show the greatest improve-
ments. The findings for age, disease duration, diabetes
complications and smoking status were less conclusive
and inconsistent across clinical outcomes.
The multilevel regression models incorporating covari-
ates related to both patients and the intervention found
one significant two-way interaction that was consistent
across all included outcomes. Thus, for patients with
poorer initial values of a particular clinical outcome, more
frequent assessment of that outcome was associated with
progressively greater health improvements than was the
case for patients with healthier baseline levels.
Discussion
Evaluating the effects of population-wide disease man-
agement interventions implemented in actual health care
settings is a complex undertaking [35]. The Dutch ex-
ample described in this paper illustrates how practical is-
sues, such as a lack of suitable control patients, can limit
the use of experimental comparisons to establish
whether a given intervention yields a ‘true’ effect. In-
deed, attributing observed changes in variable measures
to the disease management approach under consider-
ation is one of the key challenges in practice-based
evaluation [5,14]. In cases like ours, where rigorous
performance assessment is complicated because data
collection is tied to the intervention and real baseline
data is lacking, a frequently used solution is to reporte
Mean difference [95% CI] Heterogeneity (I2)
0.17 [−0.60, 0.93] 98%*
−0.09 [−0.13, -0.05]* 93%*
−0.95 [−1.25, -0.64]* 57%*
−0.04 [−0.10, 0.02] 0%
Table 4 Effect of active intervention features and patient characteristics on changes in HbA1c, LDL and SBP over
baseline and associated changes in between-group(τ2) and within-group(σ2) variance in effects
HbA1c LDL SBP
N Mean difference [95% CI] RC N Mean difference [95% CI] RC N Mean difference [95% CI] RC
Active intervention features
Measurement frequency - -* -*
≤Median 27,322 0.09 [−0.85, 1.03] 25,420 −0.08* [−0.12, -0.05] 21,764 −0.99* [−1.57, -0.41]
>Median 20,913 −0.06 [−1.47, 1.36] 10,782 −0.20* [−0.26, -0.15] 25,824 −1.01* [−1.38, -0.64]
Measurement range -* - +*
<8 outcomes 15,641 0.13 [−1.08, 1.34] 6500 −0.10* [−0.15, -0.05] 14,397 −1.60* [−2.02, -1.17]
8 outcomes 51,820 0.05 [−0.66, 0.75] 45,301 −0.10* [−0.14, -0.06] 50,392 −0.79* [−1.15, -0.43]
Length of follow-up +* +* +*
≤1 year 57,069 0.02 [−0.77, 0.81] 43,901 −0.09* [−0.13, -0.05] 55,686 −1.27* [−1.60, -0.95]
>1 year 18,058 0.53 [−0.22, 1.27] 14,796 −0.11* [−0.15, -0.06] 17,751 −0.04 [−0.52, 0.44]
Change in τ2 26.0% −37.0% 15.6%
Change in σ2 −0.1% 0.7% 5.2%
Patient characteristics
Age -* +* +*
≤59 20,538 0.21 [−0.56, 0.98] 15,857 −0.12* [−0.16, -0.07] 20,139 −0.57* [−0.92, -0.23]
60-69 24,204 0.23 [−0.55, 1.02] 19,364 −0.09* [−0.13, -0.05] 23,689 −1.00* [−1.38, -0.62]
≥70 30,382 0.03 [−0.78, 0.83] 23,474 −0.08* [−0.12, -0.03] 29,605 −1.34* [−1.72, -0.96]
Disease duration +* - +
≤2 21,261 -0.12 [−1.12, 0.88] 16,756 −0.14* [−0.19, -0.08] 21,673 −1.04* [−1.47, -0.62]
3-5 13,342 0.11 [−0.76, 0.98] 10,607 −0.08* [−0.12, -0.03] 13,117 −0.55* [−0.97, -0.13]
≥6 20,474 −0.07 [−1.08, 0.95] 15,857 −0.06* [−0.10, -0.01] 19,645 −1.22* [−1.61, -0.84]
Baseline health -* -* -*
Good 51,545 1.79* [1.17, 2.41] 29,311 0.15* [0.12, 0.18] 42,784 4.59 [4.21, 4.97]
Moderate 21,637 −2.62* [−3.46, -1.78] 19,984 −0.17* [−0.20, -0.14]
Poor 1945 −16.82* [−18.7,-15.0] 9402 −0.72* [−0.77, -0.67] 30,653 −8.91 [−9.67, -8.16]
Diabetes complications +* -* -*
No 53,065 0.04 [−0.63, 0.71] 39,721 −0.10* [−0.14, -0.06] 50,780 −0.93* [−1.29, -0.58]
Yes 10,183 −0.06 [−0.76, 0.65] 7994 −0.08* [−0.15, -0.01] 9788 −1.25* [−1.75, -0.75]
Smoking status +* - -
No/previously 46,277 0.23 [−0.28, 0.73] 38,294 −0.09* [−0.13, -0.04] 46,908 −0.90* [−1.24, -0.56]
Yes 10,375 0.20 [−0.85, 1.25] 7762 −0.11* [−0.15, -0.06] 10,504 −1.07* [−1.54, -0.59]
Change in τ2 −12.5% −33.9% 74.8%
Change in σ2 −23.5% −21.7% −29.9%
NOTE: N indicates number of patients, CI, confidence interval, RC, regression coefficient, +, positive regression slope, -, negative regression slope, *statistically
significant (p < 0.05), baseline health status is defined according to the target values of the national diabetes care standard: Good (HbA1c ≤ 53 mmol/mol, LDL <
2.5 mmol/l, SBP ≤ 140 mmHg), Moderate (HbA1c 54-74 mmol/mol, LDL 2.5-3.5 mmol/l), Poor (HbA1c ≥ 75 mmol/mol, LDL > 3.5 mmol/l, SBP > 140 mmHg).
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use changes from this baseline as estimates of effects [6].
Such an observational approach is susceptible to various
sources of confounding and bias, which threaten the
internal validity of study results and cannot always be
observed and/or measured so as to enable statistical
adjustment. In evaluating complex health service in-
novations such as disease management, however, evenrandomization is unlikely to successfully control for
the large number of factors and interactions on diffe-
rent levels that might influence outcomes [36].
Although results must be interpreted with caution,
given the methodological limitations of uncontrolled
research, the value of our proposed methods lies in the
opportunity to analyze routine data from clinical prac-




Figure 3 Glycemic control (mmol/mol) from baseline to follow-up according to the target values of the Dutch care standard for type 2
diabetes mellitus.
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Rather than providing a single effect estimate across
many patients, which offers little guidance on what
works and for whom, multilevel regression models allow
researchers to capitalize on existing heterogeneity in ef-
fects by conducting a more granular assessment of the
impact of an intervention’s features on the health out-
comes of different patient groups. Our univariate ana-
lysis results demonstrate that a simple, unclustered
comparison of Dutch disease management patients’
baseline and follow-up clinical measures would have led
to the conclusion that the effects of the intervention are
small at best. Yet our multilevel regression findings re-
veal that for patients with poor baseline clinical values,
disease management was associated with significant and
clinically relevant health improvements after a median
follow-up of 12 months. Although this might suggest re-
gression to the mean, which is a common phenomenon
in disease management research, this is to some extent
refuted by the small percentage of patients (17% for
HbA1c) in the healthiest disease categories whose
clinical values moved towards to the mean, despite the
degenerative nature of diabetes. A 2008 large-scale,
practice-based disease management evaluation conducted
in Germany [4] as well as a recent meta-analysis of 41
RCTs [10] also found that disease management is most
beneficial for poorly controlled diabetes patients, which –
given that the vast majority of our patients had healthy
baseline values of most clinical parameters – provides a
plausible explanation for the small average effects of theDutch disease management strategy for type 2 diabetes on
health outcomes.
With regard to the effectiveness of different interven-
tion features, our covariate analyses suggest that particu-
larly for patients with poor disease control, intensive
monitoring of clinical values might be an important
intervention feature that is associated with better health
outcomes. Other studies of disease management for
diabetes have shown a similar association between more
intensive interventions and better glycemic control
[10,37]. The well-known population management model
used by Kaiser Permanente divides patients with chronic
conditions into three distinct groups based on their
degree of need: (1) supported self-management, for pa-
tients with a relatively low level of need for health care
(65-80%), (2) disease management, for patients at
increased risk because their condition is unstable (15-
30%), and (3) case management, for highly complex pa-
tients requiring active management by specialists (5%),
such as type 1 diabetes patients in the Netherlands
[38,39]. Further research is necessary to assess whether
intensive disease management might indeed be redun-
dant for the relatively healthy subgroup of diabetes
patients and could be substituted by adequate self-
management support programs that integrate primary
care and community services [40]. Future studies might
also investigate the impact of passive intervention
characteristics (i.e. setting features) on changes in pa-
tients’ health outcomes. While a separate, unreported
analysis of four passive intervention characteristics in
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groups (pilot vs. non-pilot), care group size, diabetes care
bundle price, and level of collaboration with specialists –
demonstrated no significance for any of the studied out-
comes, other factors could be of more relevance [5].
Also in line with previous research, we found that
longer length of follow-up was accompanied by less
positive effects on clinical outcomes [10,11]. Although
this seems counterintuitive, given that increased meas-
urement frequency was accompanied by better results,
there is no dose–response relationship in the Dutch
disease management approach, which means that pa-
tients with a longer observation period were not neces-
sarily seen more often than patients followed over a
shorter time frame. A plausible explanation for the iden-
tified association between length of follow-up and clin-
ical outcomes could be that the positive effects of
education on patients’ self-management behavior – and,
consequently, their glycemic control – are difficult to
maintain over time, which means that effects measured
after a short duration of care might be overestimated
[41,42].
Limitations
Although our findings are confirmed by previous ran-
domized research, the trends in outcome measures
presented here may have alternative explanations that
cannot be explored within the available data. A cautious
approach would therefore be to treat these results as
exploratory and look for further opportunities to con-
firm them in other settings, perhaps using historical
benchmarking data derived from a comparable popula-
tion (matched within strata) and corrected for secular
trends. In particular the counter-intuitive association be-
tween length of follow-up and clinical outcomes might
be explained by some unmeasured confounders, such as
patients’ socioeconomic status or educational level, both
of which are known to greatly influence individuals’
health behavior [43]. Alternatively, the lack of pre-
intervention data may have introduced post-treatment
bias, which leads to underestimation of intervention
effects and could also to some extent explain results not
lasting over time. Future research would benefit from
analyzing multiple repeated measurements over time,
the opportunity for which was limited in this study due
to the recent implementation of the studied disease
management strategy in the Netherlands.
Bias might also have been introduced by missing
values, which were numerous in the routine data pro-
vided by our 18 care groups and necessitated exclusion
of 28 to 44% of patients across the four outcome-
specific analyses. Nonetheless, our findings cover a
relatively large population (approximately 14% of known
diabetes patients in the Netherlands in 2011 [44]), whichdid not differ from other diabetes populations studied in
the Netherlands in terms of average age and disease
duration, nor was the percentage of smokers different
from that in the overall Dutch population [21,45,46].
The prevalence of diabetes complications, however, was
considerably lower in our research group as compared
to the total population of Dutch diabetes patients [47].
This observation might signify registration problems but
could also indicate that patients with co-occurring con-
ditions are more likely to be treated by specialists than
by primary care providers.
Conclusions
Despite concerted efforts to adjust for potential sources
of confounding and bias, there ultimately are limits to
the validity and reliability of findings from uncontrolled
research based on routine intervention data. While our
findings are supported by previous randomized research
in other settings, the trends in outcome measures
presented here may have alternative explanations.
Further practice-based research, perhaps using historical
data to retrospectively construct a control group, is
necessary to confirm results and learn more about the
impact of population-wide disease management.
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